BioSpace News Archive

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021 , after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company’s performance and answer questions.

Licensing agreement with Diurnal Group plc supports mission to provide individuals and families in China affected by rare diseases with the most effective medicines available in the world

Top industry leaders and venture firms unite behind Ukko’s efforts to eliminate the world’s most prevalent food allergies and sensitivities, including peanuts and gluten

Nevro Company to Host Conference Call on Wednesday, February 24, 2021, at 1:30 pm PT / 4:30 pm ET

Heat Biologics, Inc.announces the publication of additional preclinical COVID-19 results in Frontiers in Immunology, a leading peer reviewed journal, which is available online.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that gammaCore Sapphire has been included in a new long-term reimbursement policy launched by Matthew Whitty, Director of Innovation Research and Life Sciences and Chief Executive of the Accelerated Access Collaborative, for and on behalf of NHS England and NHS Improvement.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has been selected as one of 17 companies included in the world’s first psychedelic Exchange Traded Fund which begins trading today on Canada’s NEO exchange under the symbol PSYK.

ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases

Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Officer